University of North Carolina at Chapel Hill, Chapel Hill, NC
Hannah McCloskey , Sean McCabe , Kathryn Gessner , Pauline Filippou , Judy Hamad , Allison Mary Deal , Angela Smith , John L. Gore
Background: Bladder cancer requires treatment and surveillance which varies in intensity by disease stage. Our objective was to evaluate stage-specific differences in generic and bladder cancer-specific quality of life (QOL) among a large bladder cancer cohort. Methods: We performed a cross-sectional survey of bladder cancer patients using the Bladder Cancer Advocacy Network Patient Survey Network and Inspire platforms to determine generic and bladder cancer-specific QOL using the EORTC QLQ-C30 and Bladder Cancer Index. Patients were also queried regarding demographic, socioeconomic and clinical characteristics. We present descriptive statistics and a multiple linear regression model to identify factors independently associated with QOL domain score. Results: 972 respondents self-identified as patients with bladder cancer. Among respondents, 41% were female and 97% were white. The mean age was 67.6 years (range 29 to 93 years). Patients identified as having non-muscle-invasive bladder cancer (NMIBC, n=578 [63%]), MIBC (n=270, 30%), and metastatic bladder cancer (n=63, 7%). On bivariable analysis (Table), lower stage was significantly associated with better generic (p<0.01) and bladder-cancer specific QOL (p<0.01). This associated persisted on multivariable analysis adjusted for age, sex, race, years since diagnosis, and comorbidity (p<0.01 for generic, urinary, sexual, and bowel QOL). Conclusions: Disease stage significantly impacts generic and bladder cancer-specific QOL among bladder cancer survivors. Differential impact by stage may be important for the development of tailored interventions to improve QOL for bladder cancer patients.
NMIBC | MIBC | Metastatic | p-value | ||||
---|---|---|---|---|---|---|---|
N= | Mean (SD) | N= | Mean (SD) | N= | Mean (SD) | ||
EORTC QLQ-C30 | 512 | 86.5 (11.2) | 270 | 83.3 (12.9) | 63 | 78.4 (13.4) | <0.0001 |
BCI-Urinary | 514 | 87.9 (14.4) | 252 | 81.9 (17.3) | 57 | 78.8 (17.9) | <0.0001 |
BCI-Sexual | 471 | 51.7 (25.5) | 235 | 41.3 (23.8) | 50 | 34.3 (20.4) | <0.0001 |
BCI-GI | 578 | 60.8 (11.0) | 270 | 58.0 (12.3) | 63 | 57.2 (11.5) | 0.0014 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2020 Genitourinary Cancers Symposium
First Author: Kathryn Gessner
2023 ASCO Genitourinary Cancers Symposium
First Author: Karim Chamie
2024 ASCO Genitourinary Cancers Symposium
First Author: Erin Petersen
2020 Genitourinary Cancers Symposium
First Author: Pauline Filippou